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DESPITE a potent armamentarium of immunosuppres-
sive agents. graft rejection remains the major barrier 
in the development of successful small intestine allotrans-
plantation. FK 506 has extremely potent immunosuppres-
sive properties. as demonstrated by in vivo and in vitro 
testing. Renal. hepatic. and cardiac allografts survive for 
prolonged periods under FK 506 immunosuppression 
alone or with Cy A and steroids. I . J In vitro FK 506 inhibits 
Iymphokine release and proliferation of lymphocytes in 
response to alloantigens at much lower concentrations 
than Cy A.· This study compares FK 506 and Cy A for their 
ability to prevent graft rejection and graft-versus-host 
disease (GVHD) in a rat small intestine allotransplantation 
model. 
MATERIALS AND METHODS 
Adult male Lewis (LEW) and ACI rats and (ACI x LEW) Ft 
progeny allowed for separate examination of graft rejection (Ft -
LEW). GVHD (LEW ... FI). or their combined effects (ACI -
LEW). Heterotopic transplantation was performed using a com-
plete jejunoileal segment with mesocaval outflow and a Thiry-
Vella loop. Acute rejection was defined as progressive stomal 
discoloration (ischemia) and death of the host. Chronic rejection 
resulted in a firm abdominal mass occurring more than 30 days 
following transplantation. A diagnosis ofGVHD was made iffour 
or more of the following signs were present: diffuse erythema. 
hyperkeratosis of the foot pads. generalized dermatitis. unkempt 
appearance. weight loss. or diarrhea.' Specimens of donor and 
host small intesune. skin. and tongue were processed for routme 
light microscopy. Kaplan-Meier survival curves were plotted for 
each group. assessed by Mantel-Cox statistical analysis. and 
reponed relative to untreated controls. Statistical compansons of 
the incidence of acute rejection or GVHD between expcnmental 
and control groups were performed using chi·square (Yates') 
analysis. 
RESULTS 
In the "rejection only" trial (FI - LEW). intramuscular 
FK 506 (2 mg/kg/d. days 0-6: then I mg/kg four times per 
day. days 8-30) allowed for significantly prolonged survival 
(83.0 :!: 82.6 days. P < 0.0022) as well as a lower incidence 
(3 of 10. P < .05) and a histologically milder form of acute 
rejection than untreated controls (9.0 :: 2.0 days: 8 of 8). In 
the ACI -+ LEW trial. FK 506-treated animals demon-
strated prolonged survival (50.6 :: 46.5 days. P < 0.0001) 
relative to the control group (7.3 :!: 1.0 days). but rejection 
was never demonstrated (0 of 10. P < 0.05) following 
treatment. and all untreated controls (11 of 11) died of 
severe acute rejection. High-dose intramuscular CyA (40 
mg/kg/d. days - 2-7) was associated with prolonged sur-
vival 04.3 :!: 35.2 days. P < 0.0007). but rejection was 
common (4 of 9, P = NS) and severe. as demonstrated in 
histologic preparations. The cessation of FK 506 was 
associated with chronic rejection and. ultimately. death of 
the animal. In the "GVHD only" trials (LEW - Fl). 
following FK 506 treatment. only a single case of GVHD 
was noted. and this process resolved within 2 weeks of its 
onset. This animal and 6 others in this group (7 of 8. P < 
0.05) never developed clinical evidence of GVHD and 
became tolerant to their graft (\88.0 :: 72.1 days. P < 
0.0002). CyA (20 mg/kg/d. days -2-14) was not associated 
with tolerance induction (38.3 :: 38.6 days. P < 0.1035) 
and fatal acute GVHD was noted in at least 2 of 6 cases (P 
= NS). Six of 14 control animals developed GVHD. and 4 
others had 3 signs of GVHD at death (13.9 :!: 6.1 days). 
Postoperative weight gain for aU groups transplanted 
with FK 506 began at approximately 9 days and. by 3 
months. the hosts had gained 25%-50% of their pretrans-
plantation weight. Rejection and GVHD were commonly 
associated with severe weight loss. 
DISCUSSION 
Small intestine allotransplantation has been unsuccessful 
primarily due to the inability to prevent graft rejection. 6 
Immunocompetent intestinal lymphocytes induce a graft-
versus-host response. which may complicate the treatment 
of rejection.7•S CyA has cunailed graft rejection in hepatic. 
renal. and cardiac models. resulting in enhanced survival in a 
variety of species. However. CyA has provided only a minor 
breakthrough in small intestine aIlotransplantation9 •1O rela-
tive to other organ systems. Traditional immunosuppressive 
agents such as azathioprine and corticosteroids were vinu-
ally ineffective. II Despite Cy A. rejection is not uncommon I: 
and high-yield. long-term survival is the exception. 13 not the 
rule. Funhermore. CyA does not prevent GVHD. especially 
after cessation of the drug. 14•U These findings associated 
with CyA have been verified in this study. The potency of 
FK 506 makes this drug an intriguing antidote for the ills of 
small intestine allotransplantation. FK 506 inhibited rejection 
when GVHD was genetically restricted and prevented the 
fatal effects of acute GVHD in a model unopposed by graft 
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SMALL INTESTINE ALLOTRANSPLANTATION IN THE RAT 
rejection. In the most clinically relevant system. ACI -
LEW. FK 506 prevented rejection during administration of 
the drug and for up to 2.5 months thereafter. but chronic 
rejection was invariably demonstrated in surviving hosts on 
cessation of the drug. Furthermore. histologic sections of 
donor intestine revealed that rejection was more severe in the 
control and CyA-treated rats than in the FK 506-treated 
animals. No histologic evidence of drug toxicity was noted. 
and weight gain occurred in all FK 506-treated groups. 
CONCLUSIONS 
Equivalent doses of FK 506 may prevent acute rejection of 
the small intestine allograft and may abrogate fatal GVHD. 
despite a significant major histocompatability complex 
(MHC)/non-MHC mismatch. FK 506 may represent a 
major breakthrough in immunosuppressive therapy. al-
though further testing is required to enhance its efficacy 
and safety. 
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